Plasma Cell Neoplasms with Spreading in the Blood and Tissues: Extramedullary Myeloma Disease, a Rare Aggressive Form of Multiple Myeloma (First of Two Parts).

Ugo Testa, Giuseppe Leone
Author Information
  1. Ugo Testa: Istituto Superiore di Sanit��.
  2. Giuseppe Leone: Universit�� Cattolica del Sacro Cuore.

Abstract

Multiple myeloma is a disease related to the proliferation of malignant plasma cells; in most patients, the disease is confined to the level of bone marrow. However, in a minority of patients, the malignant plasma cells are also localized outside the bone marrow, either at the level of peripheral blood (plasma cell leukemia) or at the level of soft tissues (extramedullary multiple myeloma). These two rare forms of aggressive MM (ultrahigh-risk (uHR) MM as MM leading to death within 24-36 months) are both associated with some molecular features and with a limited response to current treatments.

Keywords

References

  1. Blood Cancer J. 2018 Nov 19;8(12):117 [PMID: 30455467]
  2. Sci Rep. 2021 Jul 19;11(1):14671 [PMID: 34282158]
  3. Leuk Res. 2022 Apr;115:106793 [PMID: 35248783]
  4. Am J Surg Pathol. 2020 Jun;44(6):838-848 [PMID: 32118627]
  5. J Clin Oncol. 2022 Jul 10;40(20):2246-2256 [PMID: 35333600]
  6. Eur J Haematol. 2024 Dec;113(6):824-832 [PMID: 39191670]
  7. Leukemia. 2022 Jan;36(1):288-291 [PMID: 34247197]
  8. Blood. 2025 Jan 2;145(1):85-97 [PMID: 39365257]
  9. Blood Cancer J. 2021 Dec 2;11(12):192 [PMID: 34857730]
  10. Leukemia. 2024 Feb;38(2):365-371 [PMID: 38245601]
  11. J Clin Oncol. 2023 May 10;41(14):2583-2593 [PMID: 36881785]
  12. J Clin Oncol. 2017 Sep 1;35(25):2911-2918 [PMID: 28686535]
  13. Blood Cancer J. 2024 May 31;14(1):90 [PMID: 38821914]
  14. J Clin Oncol. 2022 Sep 20;40(27):3120-3131 [PMID: 35666982]
  15. Front Oncol. 2022 Feb 08;12:820768 [PMID: 35211412]
  16. Am J Hematol. 2024 Dec;99(12):2286-2295 [PMID: 39194355]
  17. Haematologica. 2024 Apr 01;109(4):1297-1300 [PMID: 37941401]
  18. Biomed Res Int. 2015;2015:787809 [PMID: 25984534]
  19. J Clin Oncol. 2023 Jan 20;41(3):708-710 [PMID: 36179274]
  20. Eur J Haematol. 2016 Jul;97(1):93-100 [PMID: 26432667]
  21. Haematologica. 2024 May 01;109(5):1514-1524 [PMID: 37855036]
  22. Blood Cancer J. 2022 Sep 16;12(9):135 [PMID: 36114167]
  23. Am J Hematol. 2023 Oct;98(10):1540-1549 [PMID: 37421603]
  24. N Engl J Med. 2022 Aug 11;387(6):495-505 [PMID: 35661166]
  25. Clin Lymphoma Myeloma Leuk. 2015 May;15(5):286-91 [PMID: 25640025]
  26. Br J Haematol. 2020 Apr;189(2):e45-e48 [PMID: 32191818]
  27. J Clin Oncol. 2023 Mar 1;41(7):1383-1392 [PMID: 36315921]
  28. F1000Res. 2022 Feb 28;11:245 [PMID: 35646332]
  29. Br J Haematol. 2015 Jun;169(6):843-50 [PMID: 26032514]
  30. Clin Lymphoma Myeloma Leuk. 2024 Mar;24(3):e104-e111.e1 [PMID: 38135634]
  31. Br J Haematol. 2015 Jun;169(6):763-5 [PMID: 25825255]
  32. Blood Cancer J. 2021 Sep 29;11(9):161 [PMID: 34588423]
  33. J Clin Oncol. 2022 Sep 20;40(27):3151-3161 [PMID: 35666958]
  34. Leukemia. 2023 Sep;37(9):1895-1907 [PMID: 37198323]
  35. Blood Cancer J. 2016 May 20;6:e426 [PMID: 27206246]
  36. Br J Haematol. 2013 Apr;161(1):87-94 [PMID: 23368088]
  37. N Engl J Med. 2022 Dec 15;387(24):2232-2244 [PMID: 36507686]
  38. Blood Cancer J. 2022 Mar 21;12(3):45 [PMID: 35314675]
  39. Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):332-339 [PMID: 38066842]
  40. FEBS Lett. 2020 Feb;594(3):452-465 [PMID: 31561267]
  41. Nat Med. 2023 Sep;29(9):2259-2267 [PMID: 37582952]
  42. Cancer Discov. 2013 Aug;3(8):862-9 [PMID: 23612012]
  43. Ann Hematol. 2012 Jul;91(7):1031-7 [PMID: 22286070]
  44. Curr Oncol Rep. 2019 Jan 28;21(1):8 [PMID: 30689121]
  45. Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e433520 [PMID: 38772002]
  46. Br J Haematol. 2024 Sep;205(3):990-998 [PMID: 38747092]
  47. Blood Cancer J. 2024 Dec 5;14(1):214 [PMID: 39632797]
  48. Leukemia. 2024 Jun;38(6):1323-1333 [PMID: 38493239]
  49. Ann Med. 2023;55(2):2281657 [PMID: 38086395]
  50. Ann Hematol. 2024 Jun;103(6):1979-1987 [PMID: 38206369]
  51. Blood. 2024 Dec 5;144(23):2375-2388 [PMID: 39172760]
  52. Adv Ther. 2024 Apr;41(4):1576-1593 [PMID: 38402374]
  53. Chin Med J (Engl). 2022 Oct 20;135(20):2500-2502 [PMID: 36583869]
  54. J Hematol Oncol. 2024 Jun 6;17(1):42 [PMID: 38845015]

Word Cloud

Created with Highcharts 10.0.0plasmamyelomacellslevelMMMyelomaMultiplediseasemalignantpatientsbonemarrowExtramedullaryrelatedproliferationconfinedHoweverminorityalsolocalizedoutsideeitherperipheralbloodcellleukemiasofttissuesextramedullarymultipletworareformsaggressiveultrahigh-riskuHRleadingdeathwithin24-36monthsassociatedmolecularfeatureslimitedresponsecurrenttreatmentsPlasmaCellNeoplasmsSpreadingBloodTissues:DiseaseRareAggressiveFormFirstTwoPartsCART-CellsCirculating

Similar Articles

Cited By

No available data.